BioHarvest Sciences Inc. ... (BHST)
| Bid | 5.5 |
| Market Cap | 109.04M |
| Revenue (ttm) | 27.68M |
| Net Income (ttm) | -8.66M |
| EPS (ttm) | -0.45 |
| PE Ratio (ttm) | -13.98 |
| Forward PE | 102.5 |
| Analyst | Buy |
| Ask | 6.91 |
| Volume | 9,937 |
| Avg. Volume (20D) | 23,461 |
| Open | 6.17 |
| Previous Close | 6.15 |
| Day's Range | 6.12 - 6.38 |
| 52-Week Range | 0.00 - 7.38 |
| Beta | 1.32 |
About BHST
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for BHST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 days ago · proactiveinvestors.com
BioHarvest inks fragrance compound deal in move into multi-billion-dollar scents marketBioHarvest Sciences Inc. (NASDAQ:BHST) said it has signed a contract to develop a plant-based fragrance compound using its patented Botanical Synthesis technology, marking the company's entry into the...
1 week ago · proactiveinvestors.com
BioHarvest Sciences advances CDMO deal with major pharmaceutical company - ICYMIBioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel joined Proactive to discuss the company's transition to stage two of its partnership with a pharmaceutical company. This marks a key milestone in ...
1 week ago · https://www.proactiveinvestors.com
Goldman Sachs hikes growth forecasts, predicts Fed will not cut rates til DecemberGoldman Sachs has upped its US growth forecasts, following the Trump administration's agreement of a 90-day pause on tariffs with China at the start of the week. The agreement will leave the US and Ch...
1 week ago · proactiveinvestors.com
BioHarvest Sciences advances CDMO project with Nasdaq-listed pharmaceutical company to next stageBioHarvest Sciences Inc. (NASDAQ:BHST) announced the successful transition of its contract development and manufacturing (CDMO) partnership with a Nasdaq-listed pharmaceutical company from Stage 1 to ...